<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00808145</url>
  </required_header>
  <id_info>
    <org_study_id>2008-108</org_study_id>
    <nct_id>NCT00808145</nct_id>
  </id_info>
  <brief_title>Study of Sorafenib, Gemcitabine, and Cisplatin in Advanced Hepatocellular Carcinoma (HCC)</brief_title>
  <official_title>A Phase II Study of Sorafenib With Gemcitabine/Cisplatin in Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lahey Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lahey Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will look at the safety and efficacy of treating advanced hepatocellular carcinoma&#xD;
      in patients who have not yet received systemic chemotherapy. Previous local treatment of&#xD;
      hepatic lesions is permitted The treatment will use a combination of three FDA approved&#xD;
      chemotherapy drugs, Gemcitabine, Cisplatin and Sorafenib. Sorafenib is FDA approved for the&#xD;
      treatment of hepatocellular cancer, gemcitabine and cisplatin are not approved for the&#xD;
      treatment of hepatocellular cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will look at the effectiveness and safety of combining gemcitabine, cisplatin and&#xD;
      sorafenib for the treatment of advanced hepatocellular carcinoma in patients with advanced&#xD;
      disease who are chemo naive. Sorafenib has shown an increase in median survival but only&#xD;
      tumor shrinkage by RECIST criteria. Since much of the morbidity and mortality of this disease&#xD;
      occurs due to continued tumor growth in an already compromised liver, decreasing the size of&#xD;
      the tumors might have significant impact on survival. The addition of traditional cytoxic&#xD;
      agents might cause measureable tumor response and add to the survival benefit already seen&#xD;
      with sorafenib. Gemcitabine and cisplatin are agents commonly used for systemic treatment of&#xD;
      this disease and have demonstrated some effectiveness in disease control rate and median time&#xD;
      to progression. Gemcitabine/Cisplatin have been used safely in combination with sorafenib in&#xD;
      patients with lung cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lack of enrollment, many screen failures and non eligible study participants&#xD;
  </why_stopped>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of the combination of gemcitabine/cisplatin/sorafenib</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of gemcitabine/cisplatin/sorafenib in shrinking tumors extending time to progression of disease</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Gemcitabine/Cisiplatin/Sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All eligible patients will receive intravenous gemcitabine/cisplatin + daily oral sorafenib until disease progression occurs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine / Cisplatin / Sorafenib</intervention_name>
    <description>All patients will receive gemcitabine 1000mg/m2 cisplatin 30mg/m2 sorafenib 400mg orally twice daily</description>
    <arm_group_label>Gemcitabine/Cisiplatin/Sorafenib</arm_group_label>
    <other_name>nexavar - sorafenib</other_name>
    <other_name>gemzar - gemcitabine</other_name>
    <other_name>cisplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hepatocellular carcinoma: diagnosed histologically, cytologically, or clinically by a&#xD;
             rising AFP &gt; 500 ng/ml in the setting of cirrhosis and a radiographically compatible&#xD;
             lesion.&#xD;
&#xD;
          -  No prior systemic therapy; local therapy such as chemoembolization, radiofrequency&#xD;
             ablation or cryoablation is allowed.&#xD;
&#xD;
          -  Measurable disease &gt; 1 cm by CT or MRI. Lesions which have received local therapy do&#xD;
             not qualify as measurable target lesions.&#xD;
&#xD;
          -  Age &gt; 18 years old&#xD;
&#xD;
          -  ECOG Performance Status 0 or 1&#xD;
&#xD;
          -  Child-Pugh status A and B&#xD;
&#xD;
          -  Adequate bone marrow, liver and renal function as assessed by the following:&#xD;
&#xD;
               -  Hemoglobin ≥ 9.0 g/dl&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1,250/mm3&#xD;
&#xD;
               -  Platelet count ≥ 80,000/mm3&#xD;
&#xD;
               -  Total bilirubin ≤ 3.0 mg/dl&#xD;
&#xD;
               -  ALT and AST ≤ 5 times the ULN&#xD;
&#xD;
               -  Amylase and lipase ≤ 1.5 times ULN&#xD;
&#xD;
               -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  Resolution of all acute toxic effects of any prior local treatment to CTC Adverse&#xD;
             Events grade £1.&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test performed&#xD;
             within 7 days prior to the start of treatment&#xD;
&#xD;
          -  Women of childbearing potential and men must agree to use adequate contraception&#xD;
             (barrier method of birth control) prior to study entry and for the duration of study&#xD;
             participation. Men should use adequate birth control for at least three months after&#xD;
             the last administration of sorafenib.&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent. A signed&#xD;
             informed consent must be obtained prior to any study specific procedures.&#xD;
&#xD;
          -  INR &lt; 1.5 or a PT/PTT within normal limits. Patients receiving anti-coagulation&#xD;
             treatment with an agent such as warfarin or heparin may be allowed to participate. For&#xD;
             patients on warfarin, the INR or PT and PTT should be measured prior to initiation of&#xD;
             sorafenib and monitored at Day 1 and Day 8 of each cycle.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior surgery, radiation or local therapy within 4 weeks.&#xD;
&#xD;
          -  Prior treatment with either sorafenib, gemcitabine, or cisplatin&#xD;
&#xD;
          -  Cardiac disease: Congestive heart failure &gt; class II NYHA. Patients must not have&#xD;
             unstable angina (anginal symptoms at rest) or new onset angina (began within the last&#xD;
             3 months) or myocardial infarction within the past 6 months.&#xD;
&#xD;
          -  Known brain metastasis. Patients with neurological symptoms must undergo a CT scan/MRI&#xD;
             of the brain to exclude brain metastasis.&#xD;
&#xD;
          -  Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.&#xD;
&#xD;
          -  Uncontrolled hypertension defined as sustained systolic blood pressure &gt; 150 mmHg or&#xD;
             diastolic pressure &gt; 90 mmHg, despite optimal medical management.&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Active clinically serious infection &gt; CTCAE Grade 2.&#xD;
&#xD;
          -  Thrombotic or embolic events such as a cerebrovascular accident including transient&#xD;
             ischemic attacks within the past 6 months.&#xD;
&#xD;
          -  Serious non-healing wound, ulcer, or bone fracture.&#xD;
&#xD;
          -  Evidence or history of bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  Major surgery, open biopsy or significant traumatic injury within 4 weeks of first&#xD;
             study drug.&#xD;
&#xD;
          -  Use of St. John's Wort or rifampin (rifampicin).&#xD;
&#xD;
          -  Known or suspected allergy to sorafenib, cisplatin, or gemcitabine.&#xD;
&#xD;
          -  Any condition that impairs patient's ability to swallow whole pills.&#xD;
&#xD;
          -  Any malabsorption problem.&#xD;
&#xD;
          -  Uncontrolled ascites (defined as not easily controlled with diuretic treatment).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith E. Stuart, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lahey Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lahey Clinic</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>December 11, 2008</study_first_submitted>
  <study_first_submitted_qc>December 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2008</study_first_posted>
  <last_update_submitted>October 21, 2014</last_update_submitted>
  <last_update_submitted_qc>October 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment of advanced liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

